Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?

Ther Deliv. 2014 Mar;5(3):239-42. doi: 10.4155/tde.13.152.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Gene Expression Regulation, Neoplastic
  • Genetic Therapy / methods*
  • Humans
  • Immunotherapy / methods
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Oligonucleotides / metabolism*
  • Oligonucleotides, Antisense / metabolism
  • RNA Interference*
  • RNA, Small Interfering / metabolism*
  • STAT3 Transcription Factor / genetics
  • STAT3 Transcription Factor / metabolism*
  • Treatment Outcome

Substances

  • Oligonucleotides
  • Oligonucleotides, Antisense
  • RNA, Small Interfering
  • STAT3 Transcription Factor